tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
PremiumRatingsHeron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
1M ago
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
Premium
Ratings
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
1M ago
Heron Therapeutics reports Q3 EPS (10c), consensus (1c)
Premium
The Fly
Heron Therapeutics reports Q3 EPS (10c), consensus (1c)
1M ago
Heron Therapeutics files $125M mixed securities shelf
PremiumThe FlyHeron Therapeutics files $125M mixed securities shelf
3M ago
Heron Therapeutics files to sell 37.91M shares of common stock for holders
Premium
The Fly
Heron Therapeutics files to sell 37.91M shares of common stock for holders
3M ago
Heron Therapeutics Signs New Headquarters Lease
Premium
Company Announcements
Heron Therapeutics Signs New Headquarters Lease
3M ago
Heron Therapeutics Signs Agreement with Patheon
PremiumCompany AnnouncementsHeron Therapeutics Signs Agreement with Patheon
4M ago
Heron Therapeutics Reports Strong Q2 2025 Results
Premium
Company Announcements
Heron Therapeutics Reports Strong Q2 2025 Results
4M ago
Heron Therapeutics: Buy Rating Maintained Amid Debt Restructuring and Growth Potential
Premium
Ratings
Heron Therapeutics: Buy Rating Maintained Amid Debt Restructuring and Growth Potential
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100